Published on March 15, 2016
Dr. Charles Craddock of the Queen Elizabeth Hospital in Birmingham, UK, describes how doctors check if an acute myeloid leukemia (AML) patient is responding to treatment. Following a round of intensive chemotherapy, a bone marrow sample is collected and tested. This helps determine if a patients has gone into remission.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
This programme has been supported by Pfizer, through an unrestricted educational grant to the Patient Empowerment Foundation
You might also like
Transcript | How do I know if my AML treatment is working?
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.
If you’re talking about patients having intensive chemotherapy, then there’s an important test that’s done about a couple of weeks after the conclusion of the first course of chemo, which is a repeat bone marrow test. The bone marrow test will have been performed to confirm the diagnosis, and then the bone marrow is repeated after the chemo to check that the leukaemia has gone. And in 70% to 80%, perhaps more, patients the bone marrow goes into remission after one course, but in some patients it needs two courses, and in some patients it actually doesn’t go into remission after two courses which obviously requires additional thinking and management. But bone marrow after the first and second course is a very important way of knowing that patients are in remission and that sets you up, really, for the next cycles of treatment or possibly transplant.